Novo Nordisk spotlights future innovations within diabetes as insulin sales recede

Novo Nordisk has two types of insulin in the works which would finally bring some much-needed innovation to the area, says Novo exec Camilla Sylvest, pointing out that the area has not received enough attention for a while.
Camilla Sylvest, executive vice president for commercial strategy and corporate affairs at Novo Nordisk | Photo: Novo Nordisk / PR
Camilla Sylvest, executive vice president for commercial strategy and corporate affairs at Novo Nordisk | Photo: Novo Nordisk / PR
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen

A number of bleak years for pharmaceutical firm Novo Nordisk’s insulin business, particularly in the US, have been replaced by a bright outlook.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading